Organisation paid for research Program year 2023 Source: CMS Open Payments

Vitreo Retinal Surgery

Neither a doctor nor a teaching hospital

Research payments

$323,724

4 payments

Through program year 2023, Vitreo Retinal Surgery is reported as receiving $323,724 in research payments, across 4 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$104	1
2021	Research	$23,846	1
2020	Research	$299,774	2

Breakdown

Who paid Research payments · program years 2020–2023

Novartis Pharmaceuticals Corporation $323,724 4 payments

Studies the money was for Research payments · program years 2020–2023

A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $303,211 2 payments
A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $20,513 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.